Company Analysis Mankind Pharma Limited
1. Summary
Advantages
- Price (2403.7 βΉ) is less than fair price (6169.89 βΉ)
- The company's current efficiency (ROE=22.77%) is higher than the sector average (ROE=10.72%)
Disadvantages
- Dividends (0%) are below the sector average (9.55%).
- The stock's return over the last year (4.99%) is lower than the sector average (12.14%).
- Current debt level 1.73% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Mankind Pharma Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 7.6% | -1.9% | 1.6% |
| 90 days | -17.2% | -12.6% | -1.4% |
| 1 year | 5% | 12.1% | 7.1% |
MANKIND vs Sector: Mankind Pharma Limited has significantly underperformed the "Healthcare" sector by -7.15% over the past year.
MANKIND vs Market: Mankind Pharma Limited has underperformed the market marginally by -2.1% over the past year.
Stable price: MANKIND is not significantly more volatile than the rest of the market on "National Stock Exchange Of India" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MANKIND with weekly volatility of 0.0959% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2403.7 βΉ) is lower than the fair price (6169.89 βΉ).
Price significantly below the fair price: The current price (2403.7 βΉ) is 156.7% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (47.2) is lower than that of the sector as a whole (59.64).
P/E vs Market: The company's P/E (47.2) is lower than that of the market as a whole (64.71).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (9.43) is higher than that of the sector as a whole (6.64).
P/BV vs Market: The company's P/BV (9.43) is higher than that of the market as a whole (6.38).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (8.74) is lower than that of the sector as a whole (9.32).
P/S vs Market: The company's P/S indicator (8.74) is lower than that of the market as a whole (18.8).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (32.07) is lower than that of the sector as a whole (141.68).
EV/Ebitda vs Market: The company's EV/Ebitda (32.07) is lower than that of the market as a whole (34.47).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 3163.13% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (3163.13%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-4.48%).
5.4. ROE
ROE vs Sector: The company's ROE (22.77%) is higher than that of the sector as a whole (10.72%).
ROE vs Market: The company's ROE (22.77%) is higher than that of the market as a whole (3.6%).
5.5. ROA
ROA vs Sector: The company's ROA (17.65%) is higher than that of the sector as a whole (7.64%).
ROA vs Market: The company's ROA (17.65%) is higher than that of the market as a whole (7.91%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.91%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (15.54%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '9.55%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
